ClinicalTrials.gg
RecruitingNCT06915974Updated Apr 8, 2025

Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients

An interventional study of Interleukin 6 in Burns, Sepsis and Septic Shock, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Ain Shams University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
25 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Burns with a site in Egypt — 16 open to participants now, 19 under way, none of them phase 3. Burns · Egypt.

Planned enrollment
19th of 61
70 · median 60
Started
2025
with 14 others
No phase
55 of 66
13 open now
Primary completion
2025-07
later than 6 of 18 live
Registered
44th of 66
by date
Lead sponsor
3 of 66
Ain Shams University

Among the 66 studies in Burns with a site in Egypt, this one is the 19th largest by planned enrollment of the 61 interventional ones that give a count, is one of 15 that started in 2025, is one of 55 with no phase, reaches primary completion later than 6 of the 18 other live ones, and was the 44th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

16 of the 66 studies in Burns with a site in Egypt are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 25 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Burns with a site in Egypt, or all of them as a file.
02

Study summary

The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.

Read the detailed description

Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10.

Treatment plan will be initiated to all patients according to the burn ICU protocol.

According to the lab results, interleukin 6 and procalcitonin will guide the investigators to take decisions regarding clinical improvement and ICU stay.

03

Conditions studied

  • Burns
  • Sepsis
  • Septic Shock
  • Death
04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.
  • patients with burn percentage of 25% to 50% of total body surface area
  • patients with second to third degree burns
  • ASA 1 and ASA 2 patients

Exclusion criteria

Exclusion Criteria:

  • Burn percentage more than 50% or less than 25% of total body surface area
  • Having diseases
  • Cancer patients
  • ASA 3 and ASA 4 patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Burn ICU patients

    Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10. Treatment plan will be initiated to all patients according to the burn ICU protocol.

    Diagnostic Test: Interleukin 6

Interventions

  • Diagnostic testInterleukin 6

    Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10

    Also known as: Procalcitonin

06

What researchers measure

Primary outcomes

  1. Occurrence of sepsis and septic shock

    Prediction of occurrence of sepsis and septic shock

    Time frame: From day 1 to day 10 in burn ICU

Secondary outcomes

  1. Length of ICU stay

    Response to treatment and length of ICU stay for over one month

    Time frame: One month after ICU admission

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All data will be shared once the study is completed

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Before 1/2026

Access criteria: Free

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jul 2025, 6 months after the start.

Of 211 non-industry interventional studies with no phase under Burns, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 6 months is below that.

Counting every sponsor, half of 240 studies reached it within 15 months; a quarter within 6 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Apr 8, 2025
StartActual
Jan 10, 2025
Primary completionEst.
Jul 10, 2025
CompletionEst.
Jul 10, 2025
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06915974
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Jan 10, 2025
Primary completion
Jul 10, 2025 (estimated)
Completion
Jul 10, 2025 (estimated)
Last update
Apr 8, 2025

Study contacts

Ahmed H Elsayed, M.B.B.CH
Contact
AhmedHanyAbdelfatah@med.asu.edu.eg
+201016305451
Ahmed H Elsayed, M.B.B.CH
principal investigator · Anaesthesia, intensive care, and pain management resident Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion